Currently out of the existing stock ratings of John Newman, 127 are a BUY (84.11%), 24 are a HOLD (15.89%).

John Newman

Work Performance Price Targets & Ratings Chart

Analyst John Newman, currently employed at CANACCORD, carries an average stock price target met ratio of 35.65% that have a potential upside of 20.21% achieved within 127 days.

John Newman’s has documented 278 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALLO, Allogene Therapeutics at 14-Mar-2025.

Wall Street Analyst John Newman

Analyst best performing recommendations are on ATRA (ATARA BIOTHERAPEUTICS).
The best stock recommendation documented was for ATRA (ATARA BIOTHERAPEUTICS) at 11/9/2023. The price target of $13 was fulfilled within 11 days with a profit of $7 (116.67%) receiving and performance score of 106.06.

Average potential price target upside

of $90.09 (16.08%) on REGN (REGENERON PHARMACEUTICALS).
of $26.66 (49.45%) on SAGE (SAGE THERAPEUTIC).
of $24.94 (55.94%) on AGIO (AGIOS PHARM).

AGIO Agios Pharm ATRA Atara Biotherapeutics IMGN ImmunoGen MCRB Seres Therapeutics OCUP Ocuphire Pharma REGN Regeneron Pharmaceuticals SESN Sesen Bio BLUE Bluebird bio RDUS Schnitzer Steel Industries ALDX Aldeyra The ARAV Aravive CELG Celgene GBT Global Blood Therapeutics SELB Selecta Biosciences SGYP Synergy Pharmaceuticals ACET Adicet Bio HSTO Histogen SAGE Sage Therapeutic ACLX Arcellx ALLO Allogene Therapeutics BCEL Atreca ONCY Oncolytics Biotech TSVT 2Seventy Bio BNTX BioNTech SE MRUS Merus BV APTO Aptose Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Gregory Renza (RBC)